Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Capital Expenditures: 2020-2025

Historic Capital Expenditures for Arcutis Biotherapeutics (ARQT) over the last 4 years, with Jun 2025 value amounting to $78,000.

  • Arcutis Biotherapeutics' Capital Expenditures was N/A to $78,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $835,000, marking a year-over-year change of. This contributed to the annual value of $143,000 for FY2024, which is 66.59% down from last year.
  • According to the latest figures from Q2 2025, Arcutis Biotherapeutics' Capital Expenditures is $78,000, which was down 87.17% from $608,000 recorded in Q1 2025.
  • In the past 5 years, Arcutis Biotherapeutics' Capital Expenditures ranged from a high of $608,000 in Q1 2025 and a low of $6,000 during Q3 2022.
  • In the last 3 years, Arcutis Biotherapeutics' Capital Expenditures had a median value of $82,000 in 2023 and averaged $179,571.
  • Per our database at Business Quant, Arcutis Biotherapeutics' Capital Expenditures skyrocketed by 1,251.22% in 2021 and then crashed by 95.62% in 2022.
  • Arcutis Biotherapeutics' Capital Expenditures (Quarterly) stood at $261,000 in 2021, then tumbled by 52.87% to $123,000 in 2022, then plummeted by 95.12% to $6,000 in 2023, then surged by 123.44% to $143,000 in 2024, then reached $78,000 in 2025.
  • Its Capital Expenditures was $78,000 in Q2 2025, compared to $608,000 in Q1 2025 and $143,000 in Q3 2024.